BCL2抗体;BCL2 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using BCL2 mouse mAb (green) and negative control (red).    

  
  

The BCL2 (B-cell lymphoma 2) protein is a key anti-apoptotic regulator encoded by the BCL2 gene, primarily located on the mitochondrial outer membrane. Discovered in 1985 through its association with chromosomal translocations in B-cell lymphomas (notably t(14;18) in follicular lymphoma), BCL2 promotes cell survival by inhibiting programmed cell death (apoptosis). It counteracts pro-apoptotic BCL2 family proteins (e.g., BAX, BAK) to maintain mitochondrial membrane integrity, preventing cytochrome c release and caspase activation.

BCL2 antibodies are critical tools in research and diagnostics. In cancer pathology, they help identify BCL2 overexpression linked to lymphomas, leukemias, and certain solid tumors. Immunohistochemistry (IHC) using BCL2 antibodies aids in distinguishing lymphoma subtypes (e.g., follicular vs. reactive hyperplasia) and assessing tumor aggressiveness. However, BCL2 expression is context-dependent; it is normally present in follicular center B-cells and some epithelial tissues.

Therapeutically, BCL2 inhibitors like venetoclax (targeting BCL2's BH3 domain) exploit its role in cancer cell survival. Recent studies also explore BCL2's involvement in drug resistance and immune evasion. Despite its prominence in apoptosis, BCL2 has non-canonical roles in autophagy, mitochondrial dynamics, and calcium signaling, complicating its functional landscape.

BCL2 antibodies remain indispensable for unraveling its dual roles in health and disease, driving advancements in precision oncology and apoptosis-targeted therapies.